Acrivon Therapeutics, Inc. (ACRV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Silvan Tuerkcan from JMP Securities maintained a Buy rating on the stock and has a $17.00 price target.
Silvan Tuerkcan’s rating is based on Acrivon Therapeutics’ promising clinical developments and strategic positioning in the oncology field. The company is advancing two clinical-stage assets, ACR-368 and ACR-2316, through its AP3 platform, which shows potential in treating advanced cancers. ACR-368, particularly in advanced/recurrent endometrial cancer, has demonstrated a high objective response rate (ORR) of 63% in biomarker-selected patients, surpassing the standard of care. This strong efficacy profile supports the potential for accelerated approval and movement into the frontline setting.
Additionally, the company’s focus on phosphoproteomics-based data introduces a novel approach in oncology, enhancing its competitive edge. The upcoming R&D event, featuring key opinion leaders, is expected to provide further insights into ACR-368’s positioning and the progress of ACR-2316. These factors collectively underpin Tuerkcan’s confidence in Acrivon’s growth prospects, justifying the Buy rating.